Rakesh Jhunjhunwala was already holding 1.90% of the stock in the company by 30 June.
Jubilant Life Sciences NSE Shares are Negative by 0.01 percent & was trading marginally higher Yesterday after Rakesh Jhunjhunwala’s Rare Enterprises bought stock in the company.
17.50 lakh shares were acquired by the private equity firm, or 1.10%, post in the company. Rare Enterprises bought 2,013,626 shares at 436.23 Rs and sold a share 2,63,626 at 435.75 Rs.
At Rs 435 per share, East Bridge Capital Master Fund also bought 12.50 lakh shares in the company, after NSE data analyzed we can say. In Mumbai, the scrip gained as much as 1.77% to trade at Rs 452.20 Yesterday.
Drug firm Jubilant Life Sciences last week fall of 7.68% in consolidated net profit at 184.98 cr Rs for the quarter ended June 30, most due to higher expenses. The company had located 200.37 cr Rs profit for the same period previous financial year, Jubilant Life Sciences said in a BSE Data.
Turn some history pages a Year ago Consolidated total revenue from operations, rose to 2,181.86 cr RS from Rs 2,078.65 cr Rs Sources Said.
The company’s total expenses for June quarter poise at 1,922.53 cr Rs against 1,779.86 cr Rs for the year-ago period.
Brokerage firm Prabhudas Lilladher report on 29 July had a ‘reduce’ rating to Jubilant Life with a price target of 433 Rs.
A price target of Rs 785, Nirmal Bang Securities had a ‘buy’ rating to Jubilant Life.
For Quick Trial – 62329-95233 |
or mail us here:info@thegrssolution.com
or visit www.thegrssolution.com
✆ -0731-4974186
